BioCardia, Inc.
BCDANasdaq
$0.83
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -63.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.9M
Enterprise Value
$8.0M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-83.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$7.8M
Free Cash Flow (TTM)
-$7.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
729.4%
ROIC
—
Debt / Equity
—
Net Cash
$951,000.00
Return 1Y
-63.8%
Company profile
BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.
- CEO
- Peter Alan Altman, PhD
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- biocardia.com
Management & directors
- Altman PeterPresident and CEO
- Gillis Edward MSenior Vice President, Devices
- Mcclung DavidChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
BCDA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.21↓ -64.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $145,000.00 | $1.0M | $1.4M | $477,000.00 | $58,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.5M | -$12.6M | -$11.9M | -$11.6M | -$8.0M | -$8.3M |
| Net income | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$12.4M | -$10.4M | -$10.6M | -$10.0M | -$7.9M | -$7.4M |
| Free cash flow | -$12.4M | -$10.5M | -$10.6M | -$10.0M | -$7.9M | -$7.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -10709.7% | -1244.3% | -880.3% | -2441.1% | -13794.8% | — |
| Net margin | -10347.6% | -1243.6% | -880.7% | -2425.8% | -13700.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.6M | -$1.8M | -$2.3M | -$2.7M | -$2.1M | -$1.5M | -$2.0M | -$2.3M |
| Net income | -$1.6M | -$1.7M | -$2.3M | -$2.7M | -$2.0M | -$1.5M | -$2.0M | -$2.3M |
| Diluted EPS | — | — | — | -$0.59 | — | — | — | -$0.21 |
| Operating cash flow | -$1.3M | -$2.6M | -$2.4M | -$1.6M | -$1.6M | -$1.7M | -$2.5M | -$1.7M |
| Free cash flow | -$1.3M | -$2.6M | -$2.4M | -$1.6M | -$1.6M | -$1.7M | -$2.5M | -$1.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -54966.7% | — | — | — | — | — | — | — |
| Net margin | -54866.7% | — | — | — | — | — | — | — |
Company news
Jun 18, 2026
Jun 5, 2026
- 45d agoSector Update: Healthcare Stocks Higher Late Afternoonfinance.yahoo.com
- 45d agoSector Update: Healthcare Stocks Gain Friday Afternoonfinance.yahoo.com
- 45d agoTop Midday Gainersfinance.yahoo.com
- 45d agoWhy Did BCDA Stock Surge More Than 50% Today?stocktwits.com
- 45d agoBioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)investorshub.advfn.com
- 45d agoFDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEFfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Altman Peter· President and CEO | Buy | 1,500 | $0.86 | $1,290.00 | filing |
| 2026-07-14 | Altman Peter· President and CEO | Buy | 2,800 | $0.88 | $2,464.00 | filing |
| 2026-07-10 | Altman Peter· President and CEO | Buy | 1,000 | $0.94 | $940.00 | filing |
| 2026-07-09 | Altman Peter· President and CEO | Buy | 1,000 | $0.90 | $900.00 | filing |
| 2026-07-08 | Altman Peter· President and CEO | Buy | 5,500 | $0.97 | $5,335.00 | filing |
| 2026-07-08 | Altman Peter· President and CEO | Buy | 5,400 | $0.96 | $5,208.30 | filing |
| 2026-07-02 | Altman Peter· President and CEO | Tax withholding | 54,606 | $1.24 | $67,711.44 | filing |
| 2026-07-02 | McClung David· Chief Financial Officer | Tax withholding | 23,125 | $1.24 | $28,675.00 | filing |
| 2026-07-02 | GILLIS EDWARD M· Senior Vice President, Devices | Tax withholding | 17,269 | $1.24 | $21,413.56 | filing |
| 2026-06-29 | Altman Peter· President and CEO | Award | 110,625 | $1.20 | $132,750.00 | filing |
| 2026-06-29 | McClung David· Chief Financial Officer | Award | 60,483 | $1.20 | $72,579.60 | filing |
| 2026-06-29 | GILLIS EDWARD M· Senior Vice President, Devices | Award | 39,521 | $1.20 | $47,425.20 | filing |
| 2026-06-23 | STERTZER SIMON H | Buy | 39,000 | $1.00 | $39,000.00 | filing |
| 2026-06-22 | STERTZER SIMON H | Buy | 70,200 | $0.92 | $64,584.00 | filing |
| 2026-06-18 | Altman Peter· President and CEO | Buy | 800 | $0.96 | $768.00 | filing |
| 2026-06-17 | Altman Peter· President and CEO | Buy | 1,500 | $0.85 | $1,275.00 | filing |
| 2026-06-09 | Altman Peter· President and CEO | Buy | 5,000 | $0.85 | $4,250.00 | filing |
| 2026-05-20 | Altman Peter· President and CEO | Buy | 1,500 | $0.92 | $1,380.00 | filing |
| 2026-05-19 | Altman Peter· President and CEO | Buy | 200 | $0.95 | $190.00 | filing |
| 2026-05-18 | Altman Peter· President and CEO | Buy | 5,700 | $0.92 | $5,244.00 | filing |
| 2026-05-15 | Altman Peter· President and CEO | Buy | 5,100 | $1.02 | $5,202.00 | filing |
| 2026-04-29 | Altman Peter· President and CEO | Buy | 5,000 | $1.11 | $5,550.00 | filing |
| 2026-04-21 | Altman Peter· President and CEO | Buy | 400 | $1.23 | $492.00 | filing |
| 2026-04-20 | Altman Peter· President and CEO | Buy | 600 | $1.23 | $738.00 | filing |
| 2026-03-25 | Altman Peter· President and CEO | Buy | 300 | $1.22 | $366.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.